abstract |
An object of the present invention is to find utility as a therapeutic agent for glaucoma by a combination of a Rho kinase inhibitor and prostaglandins. The combination of Rho kinase inhibitors and prostaglandins complements and / or enhances intraocular pressure lowering effects. As an administration form, you may administer together, and you may administer as a mixture. |